Cantor Fitzgerald Maintains Overweight on Aerie Pharmaceuticals, Lowers Price Target to $30

Cantor Fitzgerald maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Overweight and lowers the price target from $62 to $30.

Benzinga · 11/07/2019 11:54

Cantor Fitzgerald maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Overweight and lowers the price target from $62 to $30.